A trial of immunotherapy plus targeted chemo for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of breast cancer called triple-negative (ER=0%, PR=0%, and HER2-negative) or a similar type (ER ≤10%, PR <10%, and HER2-negative).
- Your breast cancer is in an early but high-risk stage (Stage II or Stage III) and has not spread to other parts of your body.
- You have already completed 9 to 12 weeks of a common chemotherapy (carboplatin + paclitaxel or similar) plus immunotherapy (pembrolizumab), finishing within the last 2 weeks.
- You are 18 years or older and able to perform daily activities with little or no help (ECOG 0-1).
- You have a tumor sample available for central testing, and your blood counts and organ function are within certain safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a combination of two targeted drugs—sacituzumab tirumotecan and anlotinib—for people with triple-negative breast cancer that has spread or cannot be removed by surgery and has already been treated with at least one prior therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.